|1.||Schneider, L: 2 articles (01/2001 - 01/2000)|
|2.||Olin, J: 2 articles (01/2001 - 01/2000)|
|3.||Luczak, S: 2 articles (01/2001 - 01/2000)|
|4.||Novit, A: 2 articles (01/2001 - 01/2000)|
|5.||Li, Chengwan: 1 article (02/2012)|
|6.||Sun, Junming: 1 article (02/2012)|
|7.||Hu, Lingling: 1 article (02/2012)|
|8.||Jiang, Donglin: 1 article (02/2012)|
|9.||Jiang, Shengyang: 1 article (02/2012)|
|10.||Hu, Feng: 1 article (02/2012)|
03/17/1978 - "A prospective study over 15 months in 100 elderly patients with signs of cerebro-vascular impairment demonstrated by psychometric testing that Hydergine (an ergot alkaloid preparation: 4.5 mg daily) compensated the signs of dementia, present in the placebo group, and in some patients actually brought about a significant improvement in mental activity. "
11/01/1976 - "Qualitative and quantitative comparisons of improvement in symptoms showed that Hydergine consistently produced statistically significant (p less than or equal to 0.05) improvement in 13 symptoms associated with dementia. "
01/01/2001 - "Because of uncertainty surrounding the efficacy of hydergine, the goals of this overview were to assess its overall effect in patients with possible dementia, and to investigate potential moderators of an effect. "
01/01/2000 - "Because of uncertainty surrounding the efficacy of hydergine, the goals of this overview were to assess its overall effect in patients with possible dementia, and to investigate potential moderators of an effect. "
01/01/2001 - "Unfortunately, most of the randomized, double-blind, and placebo-controlled trials of hydergine were conducted and published before the advent of consensus-based diagnostic standards of dementia in 1984; therefore diagnostic criteria were less specific. "
|2.||Alzheimer Disease (Alzheimer's Disease)
08/16/1990 - "Lack of efficacy of hydergine in patients with Alzheimer's disease."
10/01/1979 - "Hydergine helpful for Alzheimer's disease."
08/16/1990 - "Eighty older adults with probable Alzheimer's disease participated in this double-blind, placebo-controlled trial of Hydergine-LC for 24 weeks. "
01/01/1996 - "Posttranslational changes in band 3 in adult and aging brain were investigated following treatment with ergoloid mesylates and compared to changes observed in Alzheimer's disease (AD). "
01/01/1996 - "Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease."
|3.||Hypertension (High Blood Pressure)
01/01/2000 - "Antihypertensive and diuretic effect of redergin confirm a pathogenetic role of deficient dopaminergic activity in development of menopausal hypertension."
01/01/2000 - "A significant fall in arterial pressure, intensive diuresis, less frequent or absent hypertensive crises, relief of menopausal symptoms were observed on day 10-14 of redergin monotherapy of menopausal patients with mild hypertension and in combined treatment of menopausal women with moderate and severe hypertension. "
01/01/1983 - "The therapeutic advantage of co-dergocrine mesylate for the treatment of hypertension in the elderly is discussed."
06/01/1964 - "[ACTION OF HYDERGINE ON HUMAN EYES AFFECTED BY VARIOUS FORMS OF HYPERTENSION]."
01/01/1958 - "[Application of redergam in the treatment of hypertension]."
03/01/1980 - "Emesis induced by i.v. hydergine, s.c. "
11/01/1966 - "Emesis induced by the intracerebroventricular administration of hydergine and mechlorethamine hydrochloride."
03/01/1988 - "It also was effective against cisplatin-induced emesis in the dog; however, it was inactive against emesis caused by apomorphine and hydergine in the same species. "
03/01/1988 - "Metoclopramide was nonselectively active against emesis induced by cytostatic agents, radiation and D2-dopamine receptor agonists, whereas domperidone was selectively effective against emesis induced by apomorphine and hydergine only. "
|3.||Dopamine Agonists (Dopamine Agonist)
|6.||Arachidonic Acid (Vitamin F)
|10.||Nitroprusside (Sodium Nitroprusside)
|2.||Drug Therapy (Chemotherapy)